v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Total revenue $ 106,030 $ 95,577
COST OF REVENUE 59,661 48,462
GROSS PROFIT 46,369 47,115
Operating expenses:    
General and administrative 36,344 32,142
Research and development 2,060 1,209
Sales and marketing 13,258 11,216
Total operating expenses 51,662 44,567
(LOSS) INCOME FROM OPERATIONS (5,293) 2,548
Interest expense, net 819 1,826
Other (income) expense (223) 5,169
Loss before taxes (5,889) (4,447)
Income tax expense (benefit) 1,089 (2,023)
NET LOSS $ (6,978) $ (2,424)
NET LOSS PER SHARE    
Basic (in dollars per share) $ (0.07) $ (0.03)
Diluted (in dollars per share) $ (0.07) $ (0.03)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares) 104,484 94,740
Diluted (in shares) 104,484 94,740
Clinical Services    
Total revenue $ 92,982 $ 86,210
GROSS PROFIT 44,059 43,559
Pharma Services    
Total revenue 13,048 9,367
GROSS PROFIT $ 2,310 $ 3,556

Source